4 results on '"Malkin M"'
Search Results
2. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
- Author
-
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, and Gutin PH
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Brain Neoplasms drug therapy, Brain Neoplasms mortality, Brain Neoplasms pathology, Disease-Free Survival, Europe, Female, Glioblastoma drug therapy, Glioblastoma mortality, Glioblastoma pathology, Humans, Israel, Kaplan-Meier Estimate, Karnofsky Performance Status, Magnetic Resonance Imaging, Male, Middle Aged, Proportional Hazards Models, Quality of Life, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, United States, Young Adult, Antineoplastic Agents therapeutic use, Brain Neoplasms therapy, Electric Stimulation Therapy adverse effects, Glioblastoma therapy, Neoplasm Recurrence, Local
- Abstract
Purpose: NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive, transducer arrays. Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division., Methods: Phase III trial of chemotherapy-free treatment of NovoTTF (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent glioblastoma. Primary end-point was improvement of overall survival., Results: Patients (median age 54 years (range 23-80), Karnofsky performance status 80% (range 50-100) were randomised to TTF alone (n=120) or active chemotherapy control (n=117). Number of prior treatments was two (range 1-6). Median survival was 6.6 versus 6.0 months (hazard ratio 0.86 [95% CI 0.66-1.12]; p=0.27), 1-year survival rate was 20% and 20%, progression-free survival rate at 6 months was 21.4% and 15.1% (p=0.13), respectively in TTF and active control patients. Responses were more common in the TTF arm (14% versus 9.6%, p=0.19). The TTF-related adverse events were mild (14%) to moderate (2%) skin rash beneath the transducer arrays. Severe adverse events occurred in 6% and 16% (p=0.022) of patients treated with TTF and chemotherapy, respectively. Quality of life analyses favoured TTF therapy in most domains., Conclusions: This is the first controlled trial evaluating an entirely novel cancer treatment modality delivering electric fields rather than chemotherapy. No improvement in overall survival was demonstrated, however efficacy and activity with this chemotherapy-free treatment device appears comparable to chemotherapy regimens that are commonly used for recurrent glioblastoma. Toxicity and quality of life clearly favoured TTF., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
3. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
- Author
-
Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL, Klang M, Lucarelli CD, Muller RJ, Eng SL, Connor M, Small TN, Brown AE, and Saltz LB
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Cost-Benefit Analysis, Feasibility Studies, Female, Fibrinolytic Agents adverse effects, Humans, Infant, Male, Middle Aged, Quality Control, Tissue Plasminogen Activator adverse effects, United States, Venous Thrombosis etiology, Catheterization, Central Venous adverse effects, Cryopreservation standards, Fibrinolytic Agents economics, Fibrinolytic Agents therapeutic use, Tissue Plasminogen Activator economics, Tissue Plasminogen Activator therapeutic use, Venous Thrombosis drug therapy
- Abstract
Purpose: To determine whether cryopreserved solutions of the thrombolytic agent alteplase could be used as a safe, effective, and economically reasonable alternative to urokinase in patients presenting with occluded central venous access devices (CVADs)., Materials and Methods: Alteplase has been reported as an efficacious alternative to urokinase for treatment of occluded CVADs. However, the practicality of using alteplase as the thrombolytic of choice for this indication remained conjectural. To make this approach economically feasible, alteplase was diluted to 1 mg/mL and 2.5-mL aliquots were stored at -20 degrees C until use. A need to confirm that the cryopreserving and thawing of the reconstituted solution did not compromise the safety and efficacy reported from prior trials was recognized. A quality assessment initiative was undertaken to concurrently monitor the safety and efficacy of this approach. Patients presenting with occluded CVADs received a sufficient volume of the thawed alteplase solution to fill the occluded catheter(s). Data, including efficacy, adverse reactions, dwell time, and catheter type, were collected over a 5-month period., Results: One hundred twenty-one patients accounting for 168 attempted clearances were assessable for safety and efficacy. One hundred thirty-six (81%) of the 168 catheter clearance attempts resulted in successful catheter clearance (95% confidence interval, 74% to 86%). No adverse events were reported., Conclusion: Cryopreserved 1-mg/mL aliquots of alteplase are safe and effective in the clearance of occluded CVADs when stored at -20 degrees C for 30 days. The ability to cryopreserve alteplase aliquots makes it an economically reasonable alternative to urokinase in the setting of CVAD occlusion.
- Published
- 2002
- Full Text
- View/download PDF
4. Physical activity programs offered in substance abuse treatment facilities.
- Author
-
Kremer D, Malkin MJ, and Benshoff JJ
- Subjects
- Adult, Dancing, Female, Health Personnel education, Humans, Interpersonal Relations, Male, Physical Education and Training, Physical Fitness psychology, Random Allocation, Sports, United States, Walking, Exercise, Recreation psychology, Substance-Related Disorders therapy
- Abstract
Responses from 50 practicing therapeutic recreation specialists indicate that physical activity programs are an important part of substance abuse treatment. Walking, games, sports, weight training, and aerobics were offered most frequently. Respondents expressed concern about their academic preparation in physical activities and offered suggestions for curricular revision. Recreation or activity therapists responding to this survey indicated that additional coursework would have prepared them more thoroughly to facilitate physical activity programs. Coursework suggested included: physical education, exercise programming, aerobics, aquatics, and physical assessment. Data indicated that over half the respondents received specialized training in physical activities after graduation through continuing education.
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.